Dr. Reddy news from FierceBiotech
News
Biotech's next big opportunity: Follow-ons?
Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...
Dr. Reddy's joins with 7TM on research pact
India's Dr. Reddy's Laboratories is teaming up with 7TM on a drug discovery deal for metabolic disorders. Both companies agreed to collaborate on selecting new drug candidates, jointly advancing them Read more...
Debate over follow-ons focus on market exclusivity
The Boston Globe weighs in with a lengthy look at the tussle over biogenerics--a.k.a. follow-ons and biosimilars. The smart money is betting that at some point in the not-too-distant future Congress Read more...
Budget has mandate for biogeneric approvals
Buried in the modest 5.7 percent budget hike for the FDA is a provision that the government will seek authority to begin approving generic versions of biologics. Despite heavy support for the Read more...
Teva snaps up CoGenesys in $400M buyout
Teva has whetted at least part of its appetite for fresh acquisitions with the announcement this morning that it is buying CoGenesys for $400 million in cash. The Israeli generic drug company says Read more...
In new approach, R&D units are spun off
In the old model for drug discovery, R&D is needed to provide a regular crop of new drug prospects to replace the therapies coming off patent. But that's not so in the generics world. Some of Read more...
SPOTLIGHT: India focuses on biosimilars
India sees a big future for itself in biogenerics. Wockhardt, Dr Reddy's Lab, Biocon, Sun Pharma, Shanta Biotech, Panacea Biotech and Ranbaxy Lab are all initiating programs Read more...
ALSO NOTED: Novartis licenses MedImmune vaccine IP; Rumor Mill: Dr. Reddy bids for Bradley; and much more...
> Rumor Mill: Generic drugmaker Dr. Reddy's Laboratories is said to have submitted a bid for U.S.-based Bradley Pharma. Read more...
Dr. Reddy's make risky biogenerics move
At the Motley Fool, Brian Orelli analyzes a recent decision by India-based generic drug developer Dr. Reddy's Laboratories to spend $20 million to produce eight new generic versions of biologics over the next eight years.
Read more...ALSO NOTED: Medarex therapy gains fast track; J&J suspends trial; and much more...
> The FDA has put Medarex's MDX-010 skin cancer therapy on the agency's fast track. Report
> Johnson & Johnson says that problems experienced by a vendor in distributing drugs for the clinical trials of golimumab for RA will force it to temporarily suspend enrollment in some Phase III studies. J&J says it will resolve the problem quickly. J&J is co-developing the drug with Schering-Plough. …
Read more...Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends